Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
The FEBS Journal
|
March 8, 2006
Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells
Paul M J Clement, Hans E Johansson, Edith C Wolff, et al.
Indian Journal of Surgical Oncology
|
August 30, 2012
Parotid carcinoma: Current diagnostic workup and treatment
Vincent L M Vander Poorten, Francis Marchal, Sandra Nuyts, et al.
Case Reports in Oncology
|
April 30, 2013
The use of high dosages of transdermal buprenorphine for pain management in palliative cancer patients: a case study
Paul M J Clement, Benoit Beuselinck, Karen Van Beek, et al.
International Journal of Cancer
|
July 13, 2002
The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro
Paul M J Clement, Hartmut M Hanauske-Abel, Edith C Wolff, et al.
Case Reports in Oncology
|
May 18, 2019
Clinically Relevant Response to Cisplatin-5-Fluorouracyl in Intestinal-Type Sinonasal Adenocarcinoma with Loss of Vision: A Case Report
Jonas Claus, Mark Jorissen, Vincent Vander Poorten, et al.
Gynecologic Oncology
|
July 21, 2004
Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva
Bernadette M Cracchiolo, Debra S Heller, Paul M J Clement, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 19, 2008
Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma
Sandra Nuyts, Piet Dirix, Paul M J Clement, et al.
The Lancet. Oncology
|
March 8, 2011
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
Jean-Pascal Machiels, Somasundaram Subramanian, Agnes Ruzsa, et al.
European Journal of Biochemistry
|
November 19, 2003
Identification and characterization of eukaryotic initiation factor 5A-2
Paul M J Clement, C Allen Henderson, Zandra A Jenkins, et al.
Journal of Pain and Symptom Management
|
April 14, 2009
Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care
Hans Wildiers, Chris Dhaenekint, Peter Demeulenaere, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
The FEBS Journal
|
March 8, 2006
Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells
Paul M J Clement, Hans E Johansson, Edith C Wolff, et al.
Indian Journal of Surgical Oncology
|
August 30, 2012
Parotid carcinoma: Current diagnostic workup and treatment
Vincent L M Vander Poorten, Francis Marchal, Sandra Nuyts, et al.
Case Reports in Oncology
|
April 30, 2013
The use of high dosages of transdermal buprenorphine for pain management in palliative cancer patients: a case study
Paul M J Clement, Benoit Beuselinck, Karen Van Beek, et al.
International Journal of Cancer
|
July 13, 2002
The antifungal drug ciclopirox inhibits deoxyhypusine and proline hydroxylation, endothelial cell growth and angiogenesis in vitro
Paul M J Clement, Hartmut M Hanauske-Abel, Edith C Wolff, et al.
Case Reports in Oncology
|
May 18, 2019
Clinically Relevant Response to Cisplatin-5-Fluorouracyl in Intestinal-Type Sinonasal Adenocarcinoma with Loss of Vision: A Case Report
Jonas Claus, Mark Jorissen, Vincent Vander Poorten, et al.
Gynecologic Oncology
|
July 21, 2004
Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva
Bernadette M Cracchiolo, Debra S Heller, Paul M J Clement, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 19, 2008
Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma
Sandra Nuyts, Piet Dirix, Paul M J Clement, et al.
The Lancet. Oncology
|
March 8, 2011
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
Jean-Pascal Machiels, Somasundaram Subramanian, Agnes Ruzsa, et al.
European Journal of Biochemistry
|
November 19, 2003
Identification and characterization of eukaryotic initiation factor 5A-2
Paul M J Clement, C Allen Henderson, Zandra A Jenkins, et al.
Journal of Pain and Symptom Management
|
April 14, 2009
Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care
Hans Wildiers, Chris Dhaenekint, Peter Demeulenaere, et al.
Page
of 2